David Schnell is a co-founder and Managing Director of Prospect
Venture Partners, a venture capital firm dedicated to investing in and supporting
emerging biomedical companies. Since 1997, Prospect has raised and managed more
than a $1B of committed capital from foundations, endowments, pension funds and
others to support innovative biomedical companies develop and commercialize novel
products and technologies to address important unmet medical needs.
David serves or has served on the Board of Directors of Gloucester Pharmaceuticals (
NASDAQ:CELG acquired), Healtheon (NASDAQ: WBMD), Kythera Biopharmaceuticals (NASDAQ: KYTH),
Microcide (NASDAQ:MCDE), Neurocrine (NASDAQ:NBIX), NGM Biopharmaceuticals, Rinat Neuroscience
(NYSE:PFE acquired), Senomyx (NASDAQ:SNMX), Trubion (NYSE: EBS acquired), Amira Pharmaceuticals
(NYSE: BMS acquired) and several other privately-held companies.
Previously, David served as a Partner at venture capital firm Kleiner Perkins Caufield
& Byers (KPCB), focusing on biotechnology and health care information technology
investing from 1993-1997. Prior to KPCB, David spent seven years at Sandoz
Pharmaceuticals (presently Novartis) in executive management positions in product
marketing, strategic operations and business development in the US and Switzerland.
In addition to his operating roles at Sandoz, David managed the company's global
venture capital investing activities in affiliation with Avalon Medical Partners
from 1992-1993. While at KPCB, David co-founded and served as the CEO of Healtheon
Corporation, a pioneering health care transaction
company that subsequently went public, and later merged with WebMD in a $6 billion transaction.
David is a Principal Partner in the San Francisco Giants, and Manager of Schnell Baseball
LLC, a limited partner in SFBA, LP. David is also the author of the award-winning children’s book, "The Night Before Baseball at the Park by the Bay”. David serves on the
Advisory Council for Make-A-Wish Foundation (Greater SF Bay Area), a non-profit
organization dedicated to fulfilling wishes of children with life-threatening medical
conditions, and previously served on the Dean of Harvard Medical School’s Therapeutics
David received an M.D. from Harvard Medical School in 1987, an M.A. in Health Services
Research from Stanford University School of Medicine, and a B.S. in Biological Sciences
from Stanford University, both in 1982.